Mi SciELO
Servicios Personalizados
Articulo
Indicadores
Citado por SciELO
Links relacionados
Similares en SciELO
Compartir
Revista Habanera de Ciencias Médicas
versión On-line ISSN 1729-519X
Resumen
FERNANDEZ ROMERO, Tammy et al. Hypoglycemic effect of NeuroEPO in diabetic and non-diabetic rats. Rev haban cienc méd [online]. 2022, vol.21, n.1 Epub 10-Mar-2022. ISSN 1729-519X.
Introduction:
NeuroEPO is a non-hematopoietic variant of human recombinant erythropoietin, which may have a hypoglycemic effect.
Objectives:
To evaluate the influence of NeuroEPO on glycemia in diabetic and non-diabetic rats.
Material and Methods:
The experiments were conducted in Wistar rats with streptozotocin-induced diabetes with and without insulin treatment, and in non-diabetic rats with glucose overload. In each experiment, one group received a subcutaneous injection of NeuroEPO (0.5 mg/kg) and the other group received a vehicle. Glycemia was determined in 120 min. Comparisons were made using one-and two-way analysis of variance, followed by the Bonferroni test. The differences were considered significant with p values < 0,05.
Results:
In diabetic rats without insulin treatment, glycemic levels decreased significantly in the group that received NeuroEPO. In nondiabetic rats that received NeuroEPO and a glucose overload, glycemia was similar to that in the control group. In diabetic rats that received NeuroEPO and insulin, the glycemia reduction was greater than in the group that only received insulin.
Conclusions:
NeuroEPO has a hypoglycemic effect in diabetic rats due to an insulinotropic mechanism that shows synergism with insulin in the treatment of hyperglycemia. However, NeuroEPO does not influence the glucose tolerance in non-diabetic rats, at least immediately. It is necessary to delve into the mechanisms by which NeuroEPO can reduce hyperglycemia and the influence of this substance under conditions of normoglycemia.
Palabras clave : diabetes mellitus; erythropoietin and cytoprotection; glucose tolerance test; insulin tolerance test; NeuroEPO; streptozotocin.